Drugs Made In America Acquisition II Corp.
DMIIFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Drugs Made In America Acquisition II Corp. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 1 annual period. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Oct 17, 2025.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Independent insiders buying near the same time
- 2025-09-26–2025-09-26: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2025-09-26–2025-09-26: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-09-26 | Drugs Made In America Acquisition II LLC · 10% owner | Ordinary shares | P — Open market or private purchase | +700,000 | unknown | SEC filing |
| 2025-09-26 | Stockwell Lynn · CEO and Exe. Chair of Board | Rights to receive ordinary shares | P — Open market or private purchase | +700,000 | unknown | SEC filing |
| 2025-09-26 | Stockwell Lynn · CEO and Exe. Chair of Board | Ordinary shares | P — Open market or private purchase | +700,000 | unknown | SEC filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC · 10% owner | Rights to receive ordinary shares | P — Open market or private purchase | +700,000 | unknown | SEC filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC · 10% owner | Ordinary shares | S — Open market or private sale | −7,966,667 | unknown | SEC filing |
| 2025-09-26 | Stockwell Lynn · CEO and Exe. Chair of Board | Ordinary shares | S — Open market or private sale | −7,966,667 | unknown | SEC filing |
Showing 6 of 6 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-09-26 | Worman Glenn C. · CFO | Ordinary shares | J — Other acquisition or disposition | +100,000 | SEC filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC · 10% owner | Ordinary shares | J — Other acquisition or disposition | −400,000 | SEC filing |
| 2025-09-26 | Shulgan Myron W. · Director | Ordinary shares | J — Other acquisition or disposition | +100,000 | SEC filing |
| 2025-09-26 | Do Catherine · Director | Ordinary shares | J — Other acquisition or disposition | +100,000 | SEC filing |
| 2025-09-26 | Stockwell Lynn · CEO and Exe. Chair of Board | Ordinary shares | J — Other acquisition or disposition | −400,000 | SEC filing |
| 2025-09-26 | Prasad Sridhar G. · Director | Ordinary shares | J — Other acquisition or disposition | +100,000 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.